Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16830244 | 1.00 | KMT2A (0.51) | KMT2ANPSR1KDM4ELMNAALDH1A1 | |
| SCHEMBL12108376 | 0.78 | CYP2C9 (0.41) | CA1CA9 | |
| SCHEMBL12108375 | 0.78 | CYP2C9 (0.41) | CA1CA9 | |
| SCHEMBL1300484 | 0.77 | EGLN1 (0.41) | KDM4EALDH1A1HTTCA1CA9 | |
| SCHEMBL1300486 | 0.77 | EGLN1 (0.41) | KDM4EALDH1A1HTTCA1CA9 | |
| SCHEMBL11530821 | 0.76 | LMNA (0.47) | KMT2ALMNATSHRALOX5POLB | |
| SCHEMBL11527702 | 0.73 | KMT2A (0.49) | KMT2ALMNAPOLBMEN1NPC1 | |
| SCHEMBL11528144 | 0.73 | CYP4F2 (0.47) | KMT2ANPSR1KDM4ELMNAALDH1A1 | |
| SCHEMBL12104209 | 0.72 | CA1 (0.43) | CA1CA9 | |
| SCHEMBL353004 | 0.72 | CA1 (0.43) | CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783511-B2 | Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease | LYCERA CORPORATION (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783511-B2 | Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease | LYCERA CORPORATION (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783511-B2 | Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease | LYCERA CORPORATION (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160311787-A1 | CARBAMATE BENZOXAZINE PROPIONIC ACIDS AND ACID DERIVATIVES FOR MODULATION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2016-10-27 | — | — | US | disclosed |
| US-20160311787-A1 | CARBAMATE BENZOXAZINE PROPIONIC ACIDS AND ACID DERIVATIVES FOR MODULATION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2016-10-27 | — | — | US | disclosed |
| WO-2015095792-A1 | CARBAMATE BENZOXAXINE PROPIONIC ACIDS AND ACID DERIVATIVES FOR MODULATION OF RORGAMMA ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311787-A1 | CARBAMATE BENZOXAZINE PROPIONIC ACIDS AND ACID DERIVATIVES FOR MODULATION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORA, RORB, RORC | KMT2A 780/4885NPSR1 1636/4885KDM4E 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.